Alexion Pharmaceuticals (ALXN) 168.22 $ALXN
Jim Cramer's 'Mad Money' Recap: 12 Stocks Even Better Than Google
at The Street - Thu Aug 21, 6:59PM CDT
Google is fabulous, Cramer says, but these stocks are just as good if not better.
Alexion Pharmaceuticals Falls 1.35% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Thu Aug 21, 4:03PM CDT
Alexion Pharmaceuticals (NASDAQ:ALXN) traded in a range yesterday that spanned from a low of $166.02 to a high of $170.45. Yesterday, the shares fell 1.3%, which took the trading range below the 3-day low of $167.55 on volume of 820,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Biotech Stock Roundup: Achillion Scores in Mid-Stage Study, Gilead's Sovaldi Remains in Focus - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Aug 20, 10:08AM CDT
Last week, hepatitis C virus treatments remained in focus with Achillion and Gilead providing updates on ACH-3102 and Sovaldi, respectively.
Amgen (AMGN) Reports Encouraging Top-Line Data on AMG 416 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Aug 19, 4:25PM CDT
Amgen Inc. (AMGN) announced that AMG 416 has met the primary as well as secondary endpoints in the second phase III registration study.
Jazz, Celgene Lead Top 4 Drugmaker Profit Margins
at Investor's Business Daily - Mon Aug 18, 12:46PM CDT
Some of the fattest annual profit margins come from drugmakers whose products are meant to make people healthier. Today's Screen of the Day is Healthy Profit Margin and includes four highly rated drug stocks. Don't miss out on Jazz Pharmaceuticals...
5 Stocks Triggering Big Breakout Trades
at The Street - Mon Aug 18, 10:12AM CDT
These stocks look poised to break out and trade higher from current levels.
SmarTrend Watching for Potential Pullback in Shares of Alexion Pharmaceuticals After 1.42% Gain
Comtex SmarTrend(R) - Fri Aug 15, 3:53PM CDT
Alexion Pharmaceuticals (NASDAQ:ALXN) traded in a range yesterday that spanned from a low of $167.24 to a high of $171.44. Yesterday, the shares gained 1.4%, which took the trading range above the 3-day high of $169.02 on volume of 1.6 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Stock Market News for August 15, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Fri Aug 15, 9:10AM CDT
Markets ended in the green as Russian president’s comments eased concerns related to geopolitical tensions
Technical Updates, Study Outcomes, Project Approvals, and Quarterly Performance Reviews - Research Reports on Alexion, Novartis, CB&I, L-3 and Emerson
PR Newswire - Fri Aug 15, 7:40AM CDT
Today, Analysts Review released its research reports regarding Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN), Novartis AG (NYSE: NVS), Chicago Bridge & Iron Company N.V. (NYSE: CBI), L-3 Communications Holdings Inc. (NYSE: LLL) and Emerson Electric Co. (NYSE: EMR). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/5765-100free.
Researchers to Present New Data on Asfotase Alfa in Pediatric Patients with Hypophosphatasia at the American Society for Bone and Mineral Research 2014 Annual Meeting
Business Wire - Wed Aug 13, 3:57PM CDT
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that new data from multiple studies of asfotase alfa in pediatric patients with hypophosphatasia (HPP) will be presented at the American Society for Bone and Mineral Research (ASBMR) 2014 Annual Meeting, which takes place September 12-15, 2014 in Houston, Texas. The meeting will feature a late-breaking abstract of survival data in pediatric patients with HPP at high risk of death who were treated with asfotase alfa, along with results from two studies in patients with perinatal, infantile and juvenile HPP who were treated with asfotase alfa for up to three years.
National Association of Professional Women Announces Donna Ames, Sr. Manager, Clinical Project Lead at Alexion Pharmaceuticals, a 2014 Professional Woman of the Year
PRWeb - Mon Aug 11, 11:03PM CDT
NAPW honors Donna Ames as a 2014 Professional Woman of the Year for coordinating clinical trials with this prestigious distinction. As the largest, most-recognized networking organization of women in the country, spanning virtually every industry and profession, the National Association of Professional Women (NAPW) is a powerfully vibrant networking community with over 600,000 members and more than 300 Local Chapters.
Alexion Pharmaceuticals Set to Possibly Pullback After Yesterday's Rally of 1.68%
Comtex SmarTrend(R) - Mon Aug 11, 4:18PM CDT
Alexion Pharmaceuticals (NASDAQ:ALXN) traded in a range yesterday that spanned from a low of $158.24 to a high of $162.18. Yesterday, the shares gained 1.7%, which took the trading range above the 3-day high of $159.60 on volume of 968,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Cannabis Should Be Treated as an Agricultural Commodity, Not a Biotech Investment
ACCESSWIRE - Mon Aug 11, 1:44PM CDT
Pittsburgh, PA / August 11, 2014 / While the future of cannabusiness is certainly bright, one controversial yet crucial caveat must be made. Pot stocks should be treated as an agricultural commodity investment rather than as a biotech investment. This is not to say that cannabis cannot be used as a pharmaceutical. It certainly can. Rather it should not be invested in as one would invest in a pharmaceutical. Taking a biotech strategy with pot stocks is the wrong road to take.
Earnings Look Back: Alexion Pharmaceuticals Is Down 5.0% Since Reporting Quarterly Results 2 Weeks Ago (ALXN)
Comtex SmarTrend(R) - Mon Aug 11, 12:08PM CDT
Two weeks ago on July 24th, 2014 Alexion Pharmaceuticals (NASDAQ:ALXN) reported earnings and analysts, on average, expected earnings of $1.07 on sales of $510.5 million. The company actually reported EPS of $1.12 on sales of $512.5 million, beating EPS estimates by $0.05 and beating revenue estimates by $2.0 million. Since the company's report, shares of Alexion Pharmaceuticals have fallen from $167.48 to $159.11, representing a loss of 5.0% in the past 18 days.
Biotech Equities Technical Momentum -- InterMune, Biogen Idec, Insmed, Dendreon, and Alexion Pharma
PR Newswire - Mon Aug 11, 7:40AM CDT
The trading session on Friday, August 08, 2014 ended on a higher note as the Dow Jones Industrial Average finished at 16,553.93, up 1.13% and the NASDAQ Composite closed at 4,370.90, up 0.83%. The S&P 500 finished the day 1.15% higher at 1,931.59. The gains were broad based as all the ten sectors finished on a positive note. The S&P 500 Health Care Sector Index finished the day at 699.99, up 1.14%, and the index has advanced 4.73% in the previous three months. Investor-Edge has initiated coverage on the following equities: InterMune Inc. (NASDAQ: ITMN), Biogen Idec Inc. (NASDAQ: BIIB), Insmed Inc. (NASDAQ: INSM), Dendreon Corp. (NASDAQ: DNDN), and Alexion Pharmaceuticals Inc. (NASDAQ: ALXN). Free research on these five companies can be accessed at:
Today's Stocks Driving Success For The Health Care Sector
at The Street - Fri Aug 08, 12:03PM CDT
TheStreet highlights 3 stocks pushing the health care sector higher today.
VIVUS Reports Narrower-than-Expected Loss on Qsymia Sales - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Aug 08, 10:00AM CDT
VIVUS Inc. (VVUS) reported second quarter 2014 loss (excluding one-time items) of 25 cents per share.
Orexigen Therapeutics Reports Wider Q2 Loss as Costs Mount - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Aug 08, 8:20AM CDT
Orexigen Therapeutics, Inc. (OREX) reported a net loss of 21 cents per share in the second quarter of 2014.
Here's How Facebook, Alexion Teach Lessons In Tenacity
at Investor's Business Daily - Thu Aug 07, 5:02PM CDT
Tenacity is among the more difficult yet more rewarding traits CAN SLIM investors eventually learn to cultivate. Buy-and-hold investors keep a stock as it spirals deep into a correction. They wager on faith that the stock will at some point rise to...
Jim Cramer's 'Mad Money' Recap: 12 Stocks Even Better Than Google
at The Street - Thu Aug 21, 6:59PM CDT
Google is fabulous, Cramer says, but these stocks are just as good if not better.
Alexion Pharmaceuticals Falls 1.35% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Thu Aug 21, 4:03PM CDT
Alexion Pharmaceuticals (NASDAQ:ALXN) traded in a range yesterday that spanned from a low of $166.02 to a high of $170.45. Yesterday, the shares fell 1.3%, which took the trading range below the 3-day low of $167.55 on volume of 820,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Biotech Stock Roundup: Achillion Scores in Mid-Stage Study, Gilead's Sovaldi Remains in Focus - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Aug 20, 10:08AM CDT
Last week, hepatitis C virus treatments remained in focus with Achillion and Gilead providing updates on ACH-3102 and Sovaldi, respectively.
Amgen (AMGN) Reports Encouraging Top-Line Data on AMG 416 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Aug 19, 4:25PM CDT
Amgen Inc. (AMGN) announced that AMG 416 has met the primary as well as secondary endpoints in the second phase III registration study.
Jazz, Celgene Lead Top 4 Drugmaker Profit Margins
at Investor's Business Daily - Mon Aug 18, 12:46PM CDT
Some of the fattest annual profit margins come from drugmakers whose products are meant to make people healthier. Today's Screen of the Day is Healthy Profit Margin and includes four highly rated drug stocks. Don't miss out on Jazz Pharmaceuticals...
5 Stocks Triggering Big Breakout Trades
at The Street - Mon Aug 18, 10:12AM CDT
These stocks look poised to break out and trade higher from current levels.
SmarTrend Watching for Potential Pullback in Shares of Alexion Pharmaceuticals After 1.42% Gain
Comtex SmarTrend(R) - Fri Aug 15, 3:53PM CDT
Alexion Pharmaceuticals (NASDAQ:ALXN) traded in a range yesterday that spanned from a low of $167.24 to a high of $171.44. Yesterday, the shares gained 1.4%, which took the trading range above the 3-day high of $169.02 on volume of 1.6 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Stock Market News for August 15, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Fri Aug 15, 9:10AM CDT
Markets ended in the green as Russian president’s comments eased concerns related to geopolitical tensions
Technical Updates, Study Outcomes, Project Approvals, and Quarterly Performance Reviews - Research Reports on Alexion, Novartis, CB&I, L-3 and Emerson
PR Newswire - Fri Aug 15, 7:40AM CDT
Today, Analysts Review released its research reports regarding Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN), Novartis AG (NYSE: NVS), Chicago Bridge & Iron Company N.V. (NYSE: CBI), L-3 Communications Holdings Inc. (NYSE: LLL) and Emerson Electric Co. (NYSE: EMR). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/5765-100free.
Researchers to Present New Data on Asfotase Alfa in Pediatric Patients with Hypophosphatasia at the American Society for Bone and Mineral Research 2014 Annual Meeting
Business Wire - Wed Aug 13, 3:57PM CDT
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that new data from multiple studies of asfotase alfa in pediatric patients with hypophosphatasia (HPP) will be presented at the American Society for Bone and Mineral Research (ASBMR) 2014 Annual Meeting, which takes place September 12-15, 2014 in Houston, Texas. The meeting will feature a late-breaking abstract of survival data in pediatric patients with HPP at high risk of death who were treated with asfotase alfa, along with results from two studies in patients with perinatal, infantile and juvenile HPP who were treated with asfotase alfa for up to three years.
National Association of Professional Women Announces Donna Ames, Sr. Manager, Clinical Project Lead at Alexion Pharmaceuticals, a 2014 Professional Woman of the Year
PRWeb - Mon Aug 11, 11:03PM CDT
NAPW honors Donna Ames as a 2014 Professional Woman of the Year for coordinating clinical trials with this prestigious distinction. As the largest, most-recognized networking organization of women in the country, spanning virtually every industry and profession, the National Association of Professional Women (NAPW) is a powerfully vibrant networking community with over 600,000 members and more than 300 Local Chapters.
Alexion Pharmaceuticals Set to Possibly Pullback After Yesterday's Rally of 1.68%
Comtex SmarTrend(R) - Mon Aug 11, 4:18PM CDT
Alexion Pharmaceuticals (NASDAQ:ALXN) traded in a range yesterday that spanned from a low of $158.24 to a high of $162.18. Yesterday, the shares gained 1.7%, which took the trading range above the 3-day high of $159.60 on volume of 968,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Cannabis Should Be Treated as an Agricultural Commodity, Not a Biotech Investment
ACCESSWIRE - Mon Aug 11, 1:44PM CDT
Pittsburgh, PA / August 11, 2014 / While the future of cannabusiness is certainly bright, one controversial yet crucial caveat must be made. Pot stocks should be treated as an agricultural commodity investment rather than as a biotech investment. This is not to say that cannabis cannot be used as a pharmaceutical. It certainly can. Rather it should not be invested in as one would invest in a pharmaceutical. Taking a biotech strategy with pot stocks is the wrong road to take.
Earnings Look Back: Alexion Pharmaceuticals Is Down 5.0% Since Reporting Quarterly Results 2 Weeks Ago (ALXN)
Comtex SmarTrend(R) - Mon Aug 11, 12:08PM CDT
Two weeks ago on July 24th, 2014 Alexion Pharmaceuticals (NASDAQ:ALXN) reported earnings and analysts, on average, expected earnings of $1.07 on sales of $510.5 million. The company actually reported EPS of $1.12 on sales of $512.5 million, beating EPS estimates by $0.05 and beating revenue estimates by $2.0 million. Since the company's report, shares of Alexion Pharmaceuticals have fallen from $167.48 to $159.11, representing a loss of 5.0% in the past 18 days.
Biotech Equities Technical Momentum -- InterMune, Biogen Idec, Insmed, Dendreon, and Alexion Pharma
PR Newswire - Mon Aug 11, 7:40AM CDT
The trading session on Friday, August 08, 2014 ended on a higher note as the Dow Jones Industrial Average finished at 16,553.93, up 1.13% and the NASDAQ Composite closed at 4,370.90, up 0.83%. The S&P 500 finished the day 1.15% higher at 1,931.59. The gains were broad based as all the ten sectors finished on a positive note. The S&P 500 Health Care Sector Index finished the day at 699.99, up 1.14%, and the index has advanced 4.73% in the previous three months. Investor-Edge has initiated coverage on the following equities: InterMune Inc. (NASDAQ: ITMN), Biogen Idec Inc. (NASDAQ: BIIB), Insmed Inc. (NASDAQ: INSM), Dendreon Corp. (NASDAQ: DNDN), and Alexion Pharmaceuticals Inc. (NASDAQ: ALXN). Free research on these five companies can be accessed at:
Today's Stocks Driving Success For The Health Care Sector
at The Street - Fri Aug 08, 12:03PM CDT
TheStreet highlights 3 stocks pushing the health care sector higher today.
VIVUS Reports Narrower-than-Expected Loss on Qsymia Sales - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Aug 08, 10:00AM CDT
VIVUS Inc. (VVUS) reported second quarter 2014 loss (excluding one-time items) of 25 cents per share.
Orexigen Therapeutics Reports Wider Q2 Loss as Costs Mount - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Aug 08, 8:20AM CDT
Orexigen Therapeutics, Inc. (OREX) reported a net loss of 21 cents per share in the second quarter of 2014.
Here's How Facebook, Alexion Teach Lessons In Tenacity
at Investor's Business Daily - Thu Aug 07, 5:02PM CDT
Tenacity is among the more difficult yet more rewarding traits CAN SLIM investors eventually learn to cultivate. Buy-and-hold investors keep a stock as it spirals deep into a correction. They wager on faith that the stock will at some point rise to...
